Viral Vector Manufacturing Facility Pty Ltd (VVMF) today announced its participation in the Alliance for Regenerative Medicine’s (ARM) Cell and Gene Meeting on the Mesa 2026, taking place in Phoenix, Arizona, from 5-7 October 2026.
Vasily Medvedev, Chief Technology Officer, and Paula Miccinesi, Head of Business Development, North America, will be available to discuss the organisation’s expertise across research, process and analytical development, GMP viral vector manufacturing, and the integrated support services that help global developers leverage the advantages of Australia’s biotechnology ecosystem.
As Australia’s only viral vector Contract Development and Manufacturing Organisation (CDMO), VVMF provides end-to-end services to the global cell and gene therapy (CGT) sector, delivering high-quality lentiviral (LV) and adeno-associated viral (AAV) vector solutions that support programs with research, clinical, and commercial needs.
Commenting on VVMF’s participation, Vasily Medvedev said: “Meeting on the Mesa is one of the key industry events in the cell and gene therapy space. We look forward to hearing about the latest advances in the field, strengthening industry connections, and sharing how VVMF’s innovative Australian CDMO model can help developers accelerate timelines, optimise costs and advance therapies toward the clinic.”
Schedule a meeting via the meeting’s one-on-one partnering platform or contact us at info@vvmf.com.au to explore how VVMF can be your trusted partner in advancing cell and gene therapies.
About VVMF – Unlocking the Future of Medicine
Viral Vector Manufacturing Facility Pty. Ltd. (VVMF) is Australia’s only Contract Development and Manufacturing Organisation (CDMO) dedicated to providing services in the research, design, development, and manufacture of viral vectors for advanced therapeutic applications. VVMF partners with researchers, clinicians, and bio-pharma companies to accelerate the path to market for cell and gene therapies to local and global patients.
Viral vectors play a crucial role in delivering genetic material into cells and are central to innovative treatments in areas of medicine including cancers and rare diseases.
Contact
For further information please contact media@vvmf.com.au